It has been reported that AMSA has antitumor activity in several human malignancies including two minor regressions in four patients with adenocarcinoma of the lung. The present study was conducted in patients having a good performance status. One third of these patients had received no prior chemotherapy. Toxicity, primarily leukopenia, did occur but no major objective responses were seen among the 22 evaluable patients. Eighteen of the patients had adenocarcinoma. At 95% confidence limits, the predicted true major response rate is <16% for patients with adenocarcinoma of the lung. We have not seen a significant difference in response rate among the subclassifications of non-small cell bronchogenic carcinoma in previous studies at this institution. Including all 22 patients, the predicted response rate of AMSA is <14% (P=0.05) for patients with non-small cell lung cancer. We conclude that AMSA, in the dose and schedule given to this population of patients, is not active as a single agent in the treatment of non-small cell carcinoma of the lung.
|Original language||English (US)|
|Number of pages||3|
|Journal||Cancer Treatment Reports|
|State||Published - 1980|
ASJC Scopus subject areas
- Cancer Research